Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | SVP, Technical Operations | March 03, 2023 | March 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date March 03, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 23,854 |
Reported balance
After 2023-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-03 · Grant · Acquired 4,373 · Balance 23,854 F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2: Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 25,560 |
Reported balance
After 2023-03-06 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-06 · Exercise / conversion · Acquired 1,706 · Balance 25,560 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 23,854 |
Reported balance
After 2023-03-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-06 · Sale · Disposed 1,706 · Balance 23,854 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 21,779 |
Reported balance
After 2023-03-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-03-07 · Sale · Disposed 2,075 · Balance 21,779 F3: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.72 · Expires 2023-05-02 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-06 · Exercise / conversion · Disposed 1,706 · Balance 0 F5: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F2: Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022.
F3: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2023 Filed Mar 8, 2023 02:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,075 | $140.76 | $292,080.94 |
DisclosureSEC source: 0001765581-23-000032 · edgardoc.xml · nonDerivative · entry 4 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,779 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 02:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,706 | $0.00 Strike: $58.72 | $0.00 |
DisclosureSEC source: 0001765581-23-000032 · edgardoc.xml · derivative · entry 5 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,706 shares Expires 2023-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 02:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,706 | $143.92 | $245,525.81 |
DisclosureSEC source: 0001765581-23-000032 · edgardoc.xml · nonDerivative · entry 3 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,854 Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 02:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 1,706 | $58.72 | $100,176.32 |
DisclosureSEC source: 0001765581-23-000032 · edgardoc.xml · nonDerivative · entry 2 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 02:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000032 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,854 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:58 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 197 | $149.33 | $29,418.01 |
DisclosureSEC source: 0001765581-22-000122 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,409 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 22:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 63 | $150.00 | $9,450.00 |
DisclosureSEC source: 0001765581-22-000114 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,606 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Includes 86 ordinary shares, share quantity adjusted for rounding, purchased on March 25, 2022 by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme in transactions exempt under Rule 16b-3(c). Also includes 121 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,747 | $148.94 | $260,192.76 |
DisclosureSEC source: 0001765581-22-000049 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,462 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.92 to $149.91 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 22:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 4,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000021 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,209 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 120 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 197 | $135.79 | $26,750.63 |
DisclosureSEC source: 0001765581-21-000127 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,468 F1 · kind: Represents shares withheld by the Issuer for cashless exercise of nonstatutory stock options solely to cover exercise price and required withholding taxes. F2 · balance_after: Includes 86 ordinary shares, share quantity adjusted for rounding, purchased on March 15, 2021 by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme in transactions exempt under Rule 16b-3(c). Also includes 123 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 20:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 63 | $134.51 | $8,474.13 |
DisclosureSEC source: 0001765581-21-000118 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,579 F1 · kind: Represents shares withheld by the Issuer for cashless exercise of nonstatutory stock options solely to cover exercise price and required withholding taxes. F2 · balance_after: Includes 86 ordinary shares, share quantity adjusted for rounding, purchased on March 15, 2021 by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme in transactions exempt under Rule 16b-3(c). Also includes 123 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,509 | $161.60 | $243,858.93 |
DisclosureSEC source: 0001765581-21-000046 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,519 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.5994 to $161.6046. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000022 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,028 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 114 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 197 | $151.93 | $29,930.21 |
DisclosureSEC source: 0001765581-20-000113 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,964 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 63 | $138.53 | $8,727.39 |
DisclosureSEC source: 0001765581-20-000097 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,161 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Includes 106 and 132 ordinary shares purchased on March 15, 2019 and March 13, 2020 respectively by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme in transactions exempt under Rule 16b-3(c). Also includes 103 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 615 | $111.49 | $68,565.74 |
DisclosureSEC source: 0001765581-20-000043 · edgardoc.xml · nonDerivative · entry 2 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,883 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $111.4701 to $111.5101. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 292 | $119.15 | $34,793.06 |
DisclosureSEC source: 0001765581-20-000043 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,498 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 279 | $119.75 | $33,410.22 |
DisclosureSEC source: 0001765581-20-000030 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,790 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000022 · edgardoc.xml · derivative · entry 2 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2030-02-26 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000022 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,069 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 81 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 29, 2019. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 23:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000094 · edgardoc.xml · nonDerivative · entry 1 Larkin Finbar · CIK 0001793243 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,988 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of November 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.